Study Links Cannabis and Tobacco Co-Use to Lower Brain Performance in At-Risk Adolescents
#68 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians screening adolescents for psychotic risk need to assess cannabis and tobacco co-use patterns, as this combination appears to produce worse cognitive outcomes than either substance alone. This finding supports recommending dual cessation interventions rather than addressing only cannabis, potentially improving neurodevelopmental prognosis in vulnerable youth. For patients at clinical high risk for psychosis, understanding that combined use poses additional cognitive risk may strengthen motivation for substance avoidance during critical brain development years.
A new study demonstrates that concurrent cannabis and tobacco use is associated with measurable cognitive deficits in adolescents with clinical high risk for psychosis, a population already vulnerable to neurodevelopmental compromise. The research identifies a synergistic harm pattern where the combination of these substances produces greater cognitive impairment than either drug alone, suggesting that dual substance use may accelerate the trajectory toward psychotic illness in susceptible youth. These findings have direct clinical relevance for providers evaluating adolescents presenting with early psychotic symptoms or those with family histories of psychosis, as substance use screening becomes critical to both risk stratification and intervention planning. The cognitive impairment documented in this at-risk group underscores the particular vulnerability of adolescent brains during critical developmental windows when cannabis and tobacco exposure may have irreversible effects on executive function and other domains essential for academic and social functioning. Clinicians should counsel adolescents with prodromal features or genetic risk for psychosis that cannabis-tobacco co-use poses compounded neurological risks beyond what either substance presents independently. For practitioners, this evidence supports intensive substance use prevention and cessation counseling as a core component of early psychosis intervention in at-risk youth.
“What we’re seeing in this research is that for vulnerable adolescents, particularly those with prodromal symptoms or family history of psychosis, the combination of cannabis and tobacco appears to have a synergistic neurotoxic effect that neither drug alone produces at the same level, and this should absolutely inform how we counsel patients and their families about risk stratification.”
💭 Clinicians working with adolescents at clinical high risk for psychosis should be aware that concurrent cannabis and tobacco use may compound neurocognitive vulnerabilities in this population, though the specific mechanisms—whether through direct neurotoxicity, inflammatory pathways, or shared predisposition to substance use—remain incompletely understood. The study’s cross-sectional design limits causal inference, and the relative contributions of cannabis dose, potency, frequency, and duration cannot be fully disentangled from tobacco’s effects or from the underlying psychotic risk itself. Additionally, socioeconomic factors, peer influences, and untreated psychiatric symptoms often co-occur with polydrug use in at-risk youth and may confound the observed associations. Nevertheless, this work provides practical justification for targeted substance use screening and brief intervention in clinical high-risk clinics, where even modest reductions in polysubstance use might help preserve cognitive trajectory during
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
